Government Assures Pharma Sector on Pricing and Regulation as officials meet industry leaders to discuss growth, investment, and patient safety. Senator Muhammad Aurangzeb, Finance Minister, emphasized support for regulatory reforms in healthcare and stable drug pricing. The Pharma Bureau delegation, led by Syed Anis Ahmed, highlighted improvements in product approvals, digitalization in pharma, and export potential. This meeting reinforced the government’s commitment to the pharmaceutical industry in Pakistan.
The discussion focused on key challenges, including pricing and availability of essential medicines. Erum Shakir Rahim and Ayesha T. Haq noted that consistent policies and governance are vital for industry stability. CEOs like Qawi Naseer and Hafsa Shamsi shared insights on innovation in the pharmaceutical sector and how investment facilitation for pharma can boost exports and local production. The Federal Board of Revenue (FBR) also outlined plans for tax system rationalization to support fiscal sustainability.
Officials stressed the importance of aligning with international regulatory standards and maintaining high patient safety and interest. Digitalization initiatives and stakeholder engagement were highlighted as tools to strengthen regulatory capacity. Authorities cited the World Health Organization (WHO) maturity levels for the drug regulator as benchmarks for further development. Macroeconomic stability and the broader economic reform agenda remain key to sustaining long-term sector growth.
The meeting concluded with a commitment to ongoing dialogue and cooperation. Effective regulation, innovation, and strategic governance in the healthcare sector will boost public health and drive economic growth. With these measures, the government aims to ensure a balanced pharmaceutical environment that benefits patients, investors, and companies alike.
